3. Umbruch 4.4..2005 - Online Pot

242 G.W. Guy and C.G. Stott
Figure 2. Schematic flow diagram of the production of GW Pharmaceuticals’ BDSs. CBDA,
cannabidiolic acid; QC, quality control; THCA, tetrahydrocannabinolic acid.
ing ∆ 9 -THC as the principal cannabinoid, and Nabidiolex ® , an extract of a
chemically and genetically characterized cannabis plant containing CBD as
the principal cannabinoid. Other BDSs may be generated from extracts high in
CBC, CBG, THC-V, cannabidivarin (CBD-V), etc.
Cannabinoid fraction
In addition to the principal cannabinoids present, each BDS contains other
cannabinoids that may contribute to the activity of the whole extract.
Non-cannabinoid fraction
Each BDS also contains a non-cannabinoid fraction, which contains terpenes,
sterols, fatty acids, anti-oxidants and flavonoids.